Cayman Chemical Co Inc.

Cayman Chemical Co Inc., a for-profit biochemical manufacturer headquartered in Ann Arbor, Michigan, supplies controlled substances, pharmaceutical-grade reference materials, analytical standards, and specialized reagents to federal law enforcement, defense, and public health agencies as a prime contractor on purchase orders and blanket purchase agreements, with no SBA set-aside designations across its prime portfolio.

The company's federal footprint centers on three core capability areas: synthesis and supply of controlled substances and novel psychoactive compounds for Drug Enforcement Administration pharmacological testing and diversion control; drug standards and screening kits for military and civilian drug testing programs; and specialized assay kits and analytical materials for public health surveillance. Cayman Chemical operates primarily as a full-and-open competitor across all 528 recent awards, with 100% prime positioning and minimal subcontracting exposure. Recent representative work includes a $349,150 purchase order from the Centers for Disease Control and Prevention Pittsburgh for Emergent Drug Panel-V2 kits and laboratory support services awarded September 30, 2026; a $230,365 DEA purchase order for synthesis of drug substances awarded January 22, 2026, stemming from a December 2025 sources-sought notice; and a $1.5 million single-award blanket purchase agreement with the Defense Health Agency through September 2027 for chemicals, synthetic cannabinoids, and novel psychoactive substances supporting military drug testing and occupational health readiness. The company also holds a National Institute of Dental and Craniofacial Research project grant awarded April 8, 2025, for development of novel epigenetic EZH2 inhibitor compounds to stimulate alveolar bone regeneration in dental applications, running through April 2027.

Customer concentration is heavily skewed toward public health and law enforcement mission areas. The top five agencies by potential-value share account for 97% of combined award value, led decisively by CDC Pittsburgh (12 awards, $36.2 million combined potential value), followed by the Defense Health Agency (12 awards, $3.2 million), the DEA (125 awards, $3.1 million), the Army Medical Command (12 awards, $1.4 million), and the Army Criminal Investigation Command (10 awards, $314 thousand). The DEA dominates by award count at 125 orders but carries relatively low per-order magnitude, while CDC Pittsburgh anchors the dollar exposure through large-value delivery orders. Recent activity has declined sharply — from 15 awards in 2022 to only 4 in 2026 year-to-date — signaling either customer consolidation or pipeline contraction. Recompete exposure in the next twenty-four months is minimal: only three awards with combined potential value of $251 thousand are scheduled for ultimate completion.

Cayman Chemical's vehicle footprint is characterized by Army and Defense Health Agency single-award and specific-agency BPAs rather than government-wide vehicles. The company places task orders under five named parent vehicles, including a Blanket Purchase Agreement (W9124912A0005) with the Army that has yielded eight task orders for $31 thousand combined value, and Indefinite Delivery Contract 75D30119D06777, likely a CDC vehicle, supporting five task orders worth $5.9 million. This vehicle structure signals deep, relationship-driven contracting with a limited set of repeat customers rather than broad GWAC or GSA Schedule participation.

The company's NAICS and PSC posture aligns tightly with its core work: 210 awards fall under All Other Basic Organic Chemical Manufacturing (NAICS 325199), with the remainder scattered across miscellaneous chemical and pharmaceutical preparation categories. Product Supply Code concentration is similarly specific: 207 awards carry PSC code for Laboratory Equipment And Supplies, 142 for Chemicals, and 74 for Drugs And Biologicals. This NAICS and PSC distribution reflects Cayman Chemical's identity as a specialized supplier of synthesized and reference materials rather than a broad contract manufacturer or service provider.

Subcontracting is negligible in Cayman Chemical's federal footprint: only two sub-awards appear in the source, representing 0.4% of total prime activity. One subcontract with Research Triangle Institute (September 2025) involved purity specifications and distribution for medications development. One grant sub-award placed Cayman Chemical scientists on an expert panel for novel psychoactive substance classification and data collection with The Fredric Rieders Family Renaissance Foundation (October 2023). The absence of significant prime-contractor relationships suggests Cayman Chemical executes federal work predominantly in its own manufacturing and analytical capacity rather than as a downstream vendor within larger systems integrations.